FluroTech

FluroTech Net Change in Cash

The Net Change in Cash of FluroTech (TEST.H.V) as of Nov 1, 2026 is 52,700.00 CAD. In the previous year, Net Change in Cash was -104,600.00 CAD — a change of -150.38% (higher).

Net Change in Cash

52,700.00CAD

YoY

-150.38%

Last updated:

Net Change in Cash of FluroTech is 2024 52,700.00 CAD. Net Change in Cash of FluroTech was 2023 -104,600.00 CAD. It decreases by -150.38% higher compared to the previous year.

The FluroTech Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2017
-45,300.00 CAD
Jan 1, 2018
1.18 M CAD
Jan 1, 2019
-1.54 M CAD
Jan 1, 2020
-1.10 M CAD
Jan 1, 2021
-65,900.00 CAD
Jan 1, 2022
-238,000.00 CAD
Jan 1, 2023
-104,600.00 CAD
Jan 1, 2024
52,700.00 CAD
The FluroTech Net Change in Cash history
YEARNet Change in CashYoY
52,700.00CAD-150.38%
-104,600.00CAD-56.05%
-238,000.00CAD+261.15%
-65,900.00CAD-94.02%
-1.10 MCAD-28.58%
-1.54 MCAD-230.20%
1.18 MCAD-2,714.13%
-45,300.00CAD+33.63%
-33,900.00CAD-32.87%
-50,500.00CAD+20.53%
-41,900.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FluroTech Stock analysis

What does FluroTech do? FluroTech Ltd. commercializes fluorescence spectroscopy technology for pandemic defense through its subsidiary FluroTest Diagnostics Systems Ltd., which develops rapid antigen testing platforms for SARS-CoV-2 and other pathogens. The company targets high-traffic environments such as schools, hospitals, stadiums, and corporate campuses with its FluroTest system, utilizing robotics automation, biochemistry, fluorescence detection, and cloud computing to deliver results. FluroTest Diagnostics Systems Ltd. focuses on high-output rapid antigen testing for pandemic defense, serving sectors including healthcare, education, and public venues. The primary buyers of FluroTech's technology are institutions requiring rapid pathogen detection in high-traffic settings, including schools, colleges, hospitals, athletic venues, and corporate campuses. These organizations purchase the FluroTest system to manage pandemic risks through automated, high-volume testing solutions. The company's revenue streams are derived from the sale and deployment of its diagnostic platform across these institutional segments. FluroTech Ltd. leverages its subsidiary FluroTest Diagnostics Systems Ltd. to commercialize the PEDDP (pandemic and emerging disease defense platform), which is designed for environments like airports, cruise terminals, and shopping centers. The company's products are sold to entities needing rapid, scalable testing solutions for SARS-CoV-2 and other pathogens, with the focus on institutional rather than individual consumers. FluroTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FluroTech stock

Net Change in Cash of FluroTech is 52,700.00 CAD in 2024.

Net Change in Cash of FluroTech changed from -104,600.00 CAD to 52,700.00 CAD, representing a -150.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash FluroTech since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's FluroTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — FluroTech

All Key Metrics — FluroTech